Genome‐wide meta‐analysis of SNP and antihypertensive medication interactions on left ventricular traits in African Americans

Anh N., Wei Zhao, Abigail S. Baldridge, Laura M. Raffield, Kerri L. Wiggins, Sanjiv J. Shah, Stella Aslibekyan, Hemant K. Tiwari, Nita A. Limdi, Degui Zhi, Colleen M. Sitlani, Kent D. Taylor, Bruce M. Psaty, Nona Sotoodehnia, Jennifer A. Brody, Laura J. Rasmussen‐Torvik, Donald M. Lloyd‐Jones, Leslie A. Lange, James G. Wilson, Jennifer A. Smith, Sharon L.r. Kardia, Thomas H. Mosley, Ramachandran S. Vasan, Donna K. Arnett, Marguerite R. IrvinMolecular 2019 · DOI

TL;DR

This study investigated how genetic variations (SNPs) interact with different classes of blood pressure medications to influence left ventricular (LV) traits in African Americans. They identified a specific genetic locus on chromosome 20 that significantly modifies the relationship between certain blood pressure drugs and LV relative wall thickness, paving the way for more personalized hypertension treatment.

What Problem Does This Paper Address?

Left ventricular hypertrophy (LVH), a thickening of the heart's main pumping chamber, is a significant risk factor for cardiovascular disease, particularly in African Americans. While blood pressure medications are effective at reducing LV mass (LVM), there's considerable variation in how individuals respond. This suggests that genetic factors might play a role in modifying treatment response. Previous studies have been limited by small sample sizes and a focus on candidate genes. This research aims to address this gap by conducting a genome-wide meta-analysis to identify genetic variants that interact with common antihypertensive drug classes to influence LV traits in a large African American cohort.

Methods

The researchers employed a multi-cohort meta-analysis approach, combining data from five observational studies involving African Americans treated for hypertension. They focused on three major classes of antihypertensive drugs: thiazide diuretics (TDs), angiotensin-converting enzyme inhibitors (ACE-Is), and dihydropyridine calcium channel blockers (dCCBs).

Key methodological aspects include:

  • Pharmacoepidemiologic Analysis: Examining the "main effects" of drug classes on LV traits (LVM and relative wall thickness - RWT) using fixed-effects inverse variance weighted meta-analyses.
  • Pharmacogenetic Analysis: Investigating SNP-by-drug interactions. This involved genome-wide association studies (GWAS) within each cohort, followed by a meta-analysis of these interaction estimates.
  • Rigorous Quality Control: Comprehensive quality control for genotyping data, including SNP call rates, minor allele frequencies, and Hardy-Weinberg equilibrium.
  • Imputation: Using a reference panel (HapMap phase 2) for imputation to impute genotypes for SNPs not directly genotyped.
  • Statistical Models: Employing linear regression, generalized estimating equations, and mixed-effects models depending on the cohort's design. For the meta-analysis, fixed-effects inverse variance weighted methods were used.
  • External Validation: Top findings were validated in an external cohort of European Americans from the HyperGEN study.

Datasets

The study utilized data from five observational epidemiology studies with African American participants:

  1. Coronary Artery Risk Development in Young Adult Study (CARDIA)
  2. Cardiovascular Health Study (CHS)
  3. Jackson Heart Study (JHS)
  4. Genetic Epidemiology Network of Atherosclerosis Study (GENOA)
  5. Hypertension Genetic Epidemiology Network (HyperGEN)

These cohorts provided data on antihypertensive treatment, echocardiographic traits (LVM, RWT, and secondary measures like e' velocity, E/e' ratio, and GLS), and genome-wide association study (GWAS) data. An external validation cohort of European Americans from the HyperGEN study was also used.

Key Insights and Ideas

  • Drug Class Differences Matter: The study confirmed that different classes of antihypertensive medications have distinct effects on LV structure. Specifically, dCCBs were associated with higher LVM compared to TDs. This reinforces the idea that drug choice can influence cardiac remodeling.
  • Genetics Modifies Treatment Response: The core insight is the identification of specific genetic variants that alter how individuals respond to antihypertensive drugs. This moves beyond simply looking at drug effects to understanding why responses vary.
  • A Novel Locus for RWT Interaction: The discovery of a genome-wide significant SNP-by-drug interaction on RWT, specifically involving dCCBs versus ACE-Is, is a major finding. This suggests a genetic pathway that influences how these drug classes affect LV wall thickness.
  • Long Noncoding RNAs in Focus: The significant interaction locus is located between two long noncoding RNA genes (LINC00687 and LOC339593). This highlights the potential role of non-coding genetic elements in pharmacogenomics, an area that is gaining increasing attention.
  • Potential for Precision Medicine: By identifying these gene-drug interactions, the research lays the groundwork for tailoring hypertension treatments based on an individual's genetic profile, potentially leading to more effective and safer outcomes.

Key Results

  • Main Effects: Dihydropyridine calcium channel blockers (dCCBs) were associated with higher left ventricular mass (LVM) compared to thiazide diuretics (TDs) (p = 0.001). No significant associations were found for ACE-Is versus TDs or dCCBs versus ACE-Is for LVM or RWT. For secondary outcomes, dCCBs were associated with higher lateral E/e' ratio compared to TDs (p = 0.006).
  • Genome-Wide Significant Interaction: A genome-wide significant SNP-by-drug interaction (p < 5 × 10⁻⁸) was identified on RWT when comparing dCCB users to ACE-I users. This effect was localized to three SNPs within a 20 kb locus on chromosome 20, between the long noncoding RNA genes LINC00687 and LOC339593. The smallest p-value observed was 4.74 × 10⁻⁸.
  • Marginally Significant Interactions: Several other loci showed marginally significant SNP-by-drug interactions for LVM and RWT across different drug comparisons. For example, SNPs near UBL3 modified the association of dCCBs with LVM compared to TDs.
  • Validation: The study attempted to validate findings in an external European American cohort. Two SNPs (rs326641 and rs326640) at the BICD1 locus showed significant interaction for LVM when comparing dCCBs to TDs (p = 0.0015 and 0.0019, respectively), consistent with the discovery cohort findings.

Limitations and Future Work

  • Cross-Sectional Design: The study's cross-sectional design limits the ability to establish causality or temporality between drug treatment, genetic variants, and LV traits.
  • Focus on Common Variants: The study was powered to detect modest-to-large interaction effect sizes for common variants. The influence of rare variants or other types of genetic variations was not assessed.
  • Limited Secondary Outcome Data: Secondary outcomes (e' velocity, E/e' ratio, GLS) were only available in two of the five cohorts, limiting statistical power for these analyses.
  • Validation Scope: While some findings were validated, the locus identified for the genome-wide significant interaction (LINC00687/LOC339593) was not available for validation in the HyperGEN EA cohort.
  • Future Work: The authors emphasize the need for replication of findings in larger, diverse populations. Sequencing studies are recommended to further investigate the identified loci and potentially discover novel variants. Future research should also aim to elucidate the biological mechanisms by which these genetic variants influence drug response and LV remodeling. The ultimate goal is to translate these findings into precision medicine approaches for hypertension management.

Summary updated

Abstract

Our study identified one locus having genome-wide significant SNP-by-drug interaction effect on RWT among dCCB users in comparison to ACE-I users. Upon additional validation in future studies, our findings can enhance the precision of medical approaches in hypertension treatment.
BibTeX
@inproceedings{n2019genomewide,
  author = {Anh N. and Wei Zhao and Abigail S. Baldridge and Laura M. Raffield and Kerri L. Wiggins and Sanjiv J. Shah and Stella Aslibekyan and Hemant K. Tiwari and Nita A. Limdi and Degui Zhi and Colleen M. Sitlani and Kent D. Taylor and Bruce M. Psaty and Nona Sotoodehnia and Jennifer A. Brody and Laura J. Rasmussen‐Torvik and Donald M. Lloyd‐Jones and Leslie A. Lange and James G. Wilson and Jennifer A. Smith and Sharon L.R. Kardia and Thomas H. Mosley and Ramachandran S. Vasan and Donna K. Arnett and Marguerite R. Irvin},
  title = {{Genome‐wide meta‐analysis of SNP and antihypertensive medication interactions on left ventricular traits in African Americans}},
  booktitle = {Molecular},
  year = {2019},
  doi = {10.1002/mgg3.788},
}
Figure